Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kassa Ayalew

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Therapeutic Drug Monitoring|September 26, 2003
Carbapenems in pediatricsKassa Ayalew, Sumati Nambiar, Yuliya Yasinskaya, et al.
Therapeutic Innovation & Regulatory Science|March 10, 2026
Lessons and Insights from a Case Study on Clinical Trial FraudCourtney McGuire, Jenn W Sellers, Cheryl Grandinetti, et al.
Therapeutic Innovation & Regulatory Science|April 30, 2026
Analyses of U.S. FDA GCP Assessments and Recommendations for Marketing Applications, 2015-2024Courtney McGuire, Michelle Foringer, David Burrow, et al.
Oncology (Williston Park, N.Y.)|August 29, 2009
Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpuraFaranak Jamali, Steven Lemery, Kassa Ayalew, et al.
Therapeutic Innovation & Regulatory Science|May 24, 2025
Keeping the End in Mind: Reviewing U.S. FDA Inspections of Submissions including Real-World DataCheryl Grandinetti, Donna R Rivera, Lee Pai-Scherf, et al.
Therapeutic Innovation & Regulatory Science|June 6, 2022
Correction to: Descriptive Analysis of Good Clinical Practice Inspection Findings from U.S. Food and Drug Administration and European Medicines AgencyJenn W Sellers, Camelia M Mihaescu, Kassa Ayalew, et al.
Therapeutic Innovation & Regulatory Science|May 24, 2022
Descriptive Analysis of Good Clinical Practice Inspection Findings from U.S. Food and Drug Administration and European Medicines AgencyJenn W Sellers, Camelia M Mihaescu, Kassa Ayalew, et al.
Therapeutic Innovation & Regulatory Science|May 31, 2022
Publisher Correction: Descriptive Analysis of Good Clinical Practice Inspection Findings from U.S. Food and Drug Administration and European Medicines AgencyJenn W Sellers, Camelia M Mihaescu, Kassa Ayalew, et al.
Clinical Pharmacology and Therapeutics|November 6, 2025
Evolving Standards: Good Clinical Practice Insights from US FDA, MHRA UK, and Health CanadaCheryl Grandinetti, Mandy Budwal-Jagait, Hocine Abid, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 31, 2019
Challenges with Novel Clinical Trial Designs: Master ProtocolsMichael Cecchini, Eric H Rubin, Gideon M Blumenthal, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Therapeutic Drug Monitoring|September 26, 2003
Carbapenems in pediatricsKassa Ayalew, Sumati Nambiar, Yuliya Yasinskaya, et al.
Therapeutic Innovation & Regulatory Science|March 10, 2026
Lessons and Insights from a Case Study on Clinical Trial FraudCourtney McGuire, Jenn W Sellers, Cheryl Grandinetti, et al.
Therapeutic Innovation & Regulatory Science|April 30, 2026
Analyses of U.S. FDA GCP Assessments and Recommendations for Marketing Applications, 2015-2024Courtney McGuire, Michelle Foringer, David Burrow, et al.
Oncology (Williston Park, N.Y.)|August 29, 2009
Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpuraFaranak Jamali, Steven Lemery, Kassa Ayalew, et al.
Therapeutic Innovation & Regulatory Science|May 24, 2025
Keeping the End in Mind: Reviewing U.S. FDA Inspections of Submissions including Real-World DataCheryl Grandinetti, Donna R Rivera, Lee Pai-Scherf, et al.
Therapeutic Innovation & Regulatory Science|June 6, 2022
Correction to: Descriptive Analysis of Good Clinical Practice Inspection Findings from U.S. Food and Drug Administration and European Medicines AgencyJenn W Sellers, Camelia M Mihaescu, Kassa Ayalew, et al.
Therapeutic Innovation & Regulatory Science|May 24, 2022
Descriptive Analysis of Good Clinical Practice Inspection Findings from U.S. Food and Drug Administration and European Medicines AgencyJenn W Sellers, Camelia M Mihaescu, Kassa Ayalew, et al.
Therapeutic Innovation & Regulatory Science|May 31, 2022
Publisher Correction: Descriptive Analysis of Good Clinical Practice Inspection Findings from U.S. Food and Drug Administration and European Medicines AgencyJenn W Sellers, Camelia M Mihaescu, Kassa Ayalew, et al.
Clinical Pharmacology and Therapeutics|November 6, 2025
Evolving Standards: Good Clinical Practice Insights from US FDA, MHRA UK, and Health CanadaCheryl Grandinetti, Mandy Budwal-Jagait, Hocine Abid, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 31, 2019
Challenges with Novel Clinical Trial Designs: Master ProtocolsMichael Cecchini, Eric H Rubin, Gideon M Blumenthal, et al.
Pageof 2